Early thymus research produced preparations containing many small proteins and peptides. These components were separated according to their physical and chemical characteristics and assigned alpha, beta and gamma designations.

Thymosin Alpha-1 became the first peptide from the alpha group to be isolated, sequenced and chemically synthesised.

It contains 28 amino-acid residues and no cysteine residues. It therefore has no disulphide bonds and does not require oxidative cysteine pairing in the way that IGF-1, AOD-9604 or certain other peptides do.

Its sequence contains numerous aspartic-acid and glutamic-acid residues, making the molecule strongly acidic.

The synthetic equivalent, thymalfasin, is manufactured to reproduce the native sequence and its essential N-terminal acetyl group.

Prothymosin alpha is an acidic intracellular protein involved in nuclear and chromatin-related biology.

The Thymosin Alpha-1 sequence forms its first 28 amino-acid residues.

Laboratory research has shown that an asparaginyl endopeptidase can cleave prothymosin alpha after Asn28 to generate Thymosin Alpha-1.

This provides a plausible processing pathway, although the location, amount and physiological significance of endogenous extracellular Thymosin Alpha-1 remain more complex than the description of a conventional secreted hormone.

The peptide was originally isolated from calf thymus tissue, but prothymosin alpha and related processing biology occur beyond the thymus.

Removing the N-terminal acetyl group creates a different chemical species.

Deletion of one or more terminal residues, incomplete peptide coupling, deamidation or oxidation can also produce related impurities.

Because the molecule contains no cysteine, disulphide mapping is not required. Identity testing must instead focus strongly on terminal structure, full sequence, mass and peptide-related impurities.

Acetate used as a counterion is not the same as the acetyl group covalently attached to the N-terminal serine.

A certificate may list the free-base molecular formula while the supplied material contains acetate. This can cause confusion about total vial mass and active peptide content.

The counterion should therefore be identified and quantified rather than inferred from a product name.

Thymosin Alpha-1 appears in Peptides UK catalogues as a lyophilised research peptide, acetate product or component of an “immune stack”.

Common commercial statements associate it with stronger immunity, fewer infections, faster recovery, protection during travel, improved vaccine response, healthy ageing, autoimmune balance, cancer support and long-COVID recovery.

These claims often combine laboratory immunology, older hepatitis studies, small vaccine trials and critical-care research without distinguishing the population or clinical endpoint.

A biomarker such as lymphocyte count, CD4-to-CD8 ratio or cytokine concentration is not automatically a measure of fewer infections, improved survival or better quality of life.

Evidence generated with a regulated thymalfasin medicine cannot establish the identity, purity, sterility or clinical equivalence of a research-market vial.

Toll-Like-Receptor Signalling

Preclinical studies propose interactions involving Toll-like receptor 2 and Toll-like receptor 9 on dendritic and other innate immune cells.

Downstream signalling may involve MyD88, NF-κB, p38 MAP kinase and the production of immune-related cytokines.

The evidence does not establish one high-affinity pharmacological receptor that explains every reported action.

Dendritic Cells

Dendritic cells detect potential threats and present antigens to T lymphocytes.

Thymosin Alpha-1 has been reported to influence dendritic-cell maturation, antigen presentation and cytokine signalling in selected models.

T Lymphocytes

Laboratory and clinical studies report changes in T-cell differentiation, proliferation, function or measured subsets.

The effect depends on baseline immune suppression, infection, accompanying medicines and the endpoint examined.

Natural Killer Cells

Some studies report increased natural-killer-cell activity or immune surveillance.

A laboratory measure of cytotoxic activity does not prove prevention or treatment of cancer.

Macrophages and Innate Immunity

Experimental work reports effects on macrophage activity, phagocytosis, inflammatory mediators and pathogen recognition.

These responses may be helpful or harmful depending on timing and disease context.

The phrase immune booster implies that a stronger response is always desirable.

In sepsis, severe viral infection and transplantation, poor outcomes can involve both immune suppression and damaging inflammation at different times.

Thymosin Alpha-1 has been proposed to support pathogen recognition and adaptive immunity while also moderating selected inflammatory pathways.

This dual description can appear attractive, but it also makes predictions difficult. The biological effect may depend on baseline immune state, timing and co-treatment.

No validated consumer test establishes that a healthy person has a Thymosin Alpha-1 deficiency requiring replacement.

An early study in healthy men reported rapid absorption after subcutaneous administration, with peak measured concentrations at approximately two hours.

The reported serum half-life was approximately two hours, and repeated daily exposure over five days did not produce clear accumulation in that study.

A serum half-life does not describe the duration of every downstream immune effect.

Peptide concentration, formulation, aggregation, route, kidney function and analytical method can all affect measured exposure.

FDA did not identify adequate route-specific evidence validating nasal products promoted online.

Chronic hepatitis B can lead to cirrhosis, liver failure and hepatocellular carcinoma.

Historical Thymosin Alpha-1 studies evaluated viral-DNA clearance, hepatitis-B-e-antigen outcomes and liver-enzyme changes.

Some small studies reported delayed viral responses after treatment had ended.

Other trials found no clear advantage when Thymosin Alpha-1 was added to pegylated interferon or entecavir.

Many older studies used insensitive viral-DNA assays, unclear composite endpoints, open-label designs or outdated comparators.

FDA’s 2024 evaluation concluded that evidence was insufficient to determine effectiveness for hepatitis B and noted the availability of authorised therapies with established efficacy.

Earlier studies examined Thymosin Alpha-1 alone or combined with interferon-based treatment.

These regimens were developed before current oral direct-acting antiviral combinations became standard.

Modern antiviral treatment produces sustained virological response rates above 90% in many patient populations.

FDA concluded that available Thymosin Alpha-1 evidence was insufficient for hepatitis C and involved comparison with older therapies having substantially lower cure rates.

Historical hepatitis-C findings therefore should not be used to encourage replacement or delay of current antiviral care.

HIV progressively damages CD4-positive T lymphocytes when it is not controlled.

Early studies investigated whether Thymosin Alpha-1 could improve lymphocyte measures or assist immune recovery.

Some studies used combinations involving older antiretroviral or interferon regimens.

The clinically established goal of current HIV treatment is sustained viral-load suppression with effective combination antiretroviral therapy.

FDA’s review did not find sufficient evidence supporting Thymosin Alpha-1 as HIV treatment.

A 1989 double-blind study enrolled 90 older men receiving influenza vaccination.

Researchers examined antibody responses after vaccination, with exploratory evidence of improved responses in selected participants.

Other small studies examined people receiving dialysis or individuals considered poor vaccine responders.

FDA noted that several studies relied on exploratory antibody assays, lacked appropriate controls or did not use prespecified clinically meaningful endpoints.

An antibody-titre change does not necessarily establish fewer infections, fewer hospital admissions or lower mortality.

Thymosin Alpha-1 is not part of routine UK vaccination guidance.

The 2013 ETASS Trial

ETASS enrolled 361 adults with severe sepsis across six hospitals in China.

Twenty-eight-day mortality was 26.0% in the Thymosin Alpha-1 group and 35.0% in the control group.

The estimated relative risk was 0.74, but the confidence interval included no benefit and the conventional non-stratified comparison did not reach statistical significance.

Improvements were reported in monocyte HLA-DR, an immune-function biomarker.

The 2025 TESTS Phase-Three Trial

TESTS enrolled 1,106 adults with sepsis across 22 centres in China.

It used a multicentre, double-blind, placebo-controlled design.

Twenty-eight-day mortality occurred in 23.4% of participants receiving Thymosin Alpha-1 and 24.1% receiving placebo.

The hazard ratio was 0.99, with a 95% confidence interval from 0.77 to 1.27.

No secondary or safety outcome differed statistically significantly between groups.

The investigators concluded that there was no clear evidence that Thymosin Alpha-1 reduced 28-day mortality.

The proposed rationale involved lymphopenia, T-cell exhaustion and dysregulated inflammation in severe COVID-19.

A small 105-participant randomised study reported lower mortality in a severe-disease subgroup receiving Thymosin Alpha-1 alongside standard care.

Retrospective cohorts and other small studies produced mixed findings.

FDA reviewed four meta-analyses. Three did not find reduced mortality, while one reported an association with lower mortality but no reduction in ventilation requirements or hospital stay.

Important limitations included small samples, retrospective designs, changing standards of care, heterogeneous definitions of severity and inconsistent reporting.

FDA concluded that information was insufficient to support Thymosin Alpha-1 for COVID-19.

The evidence does not establish prevention of infection, treatment of mild outpatient disease or benefit for long COVID.

Biological Rationale

Tumours can suppress antigen presentation, T-cell function and natural-killer-cell activity.

Thymosin Alpha-1 has therefore been investigated as a way to modify immune responses alongside chemotherapy, interferon, immunotherapy or local cancer treatment.

Melanoma

Older studies examined combinations with interferon or chemotherapy.

FDA concluded that the studies did not demonstrate statistically significant, clinically meaningful improvements using contemporary standards.

Hepatocellular Carcinoma

Small and frequently non-randomised studies investigated recurrence, survival or response after surgery and other treatment.

The contribution of Thymosin Alpha-1 could not be separated reliably from accompanying therapies.

FDA concluded that evidence was insufficient for hepatocellular carcinoma.

Non-Small-Cell Lung Cancer

Older studies and meta-analyses reported immune-marker or response signals when Thymosin Alpha-1 was added to chemotherapy.

The evidence predates much of the current targeted-therapy and immune-checkpoint-inhibitor landscape.

FDA concluded that effectiveness for non-small-cell lung cancer had not been demonstrated.

Haematopoietic stem-cell transplantation can produce prolonged immune suppression and serious bacterial, viral or fungal infections.

Thymosin Alpha-1 studies examined immune-cell recovery, infection markers and outcomes after transplantation.

Populations, transplant types, conditioning regimens, antimicrobial prevention and immune-suppression strategies varied considerably.

FDA concluded that the identified studies did not demonstrate reduced infections or infection-related mortality.

Transplant recipients require specialist management, and experimental immunomodulation can interact with graft-versus-host disease, rejection biology and anti-infective treatment.

Small studies have examined acute exacerbations of chronic obstructive pulmonary disease, pulmonary-function measurements and immune markers.

FDA identified limitations including small samples, short duration, incomplete reporting, uncertain blinding and lack of meaningful clinical endpoints.

It concluded that evidence did not support Thymosin Alpha-1 for COPD.

Claims that it prevents seasonal infections or shortens every respiratory illness have not been established through a large contemporary clinical programme.

Myalgic encephalomyelitis and chronic fatigue syndrome are complex conditions involving post-exertional symptom worsening, impaired function and other systemic symptoms.

Online clinics sometimes infer benefit from immune-marker abnormalities or theories of latent viral reactivation.

FDA did not identify clinical studies supporting Thymosin Alpha-1 for ME/CFS.

Evidence from acute infection, sepsis or vaccination cannot establish improvement in chronic post-exertional illness.

No reliable clinical programme establishes benefit for long COVID, chronic fatigue, unexplained low energy or “immune exhaustion”.

The thymus becomes smaller and less active with age, and older adults can have weaker responses to some infections and vaccines.

Small vaccine studies and immunology research have explored whether Thymosin Alpha-1 can improve selected immune responses in older people.

No controlled evidence establishes that it slows biological ageing, prevents age-related disease or extends human lifespan.

Ageing involves cardiovascular, metabolic, neurological, musculoskeletal and immune systems. Altering one immune pathway cannot be assumed to improve the complete ageing process.

There is no recognised diagnostic category of low Thymosin Alpha-1 in otherwise healthy adults requiring routine replacement.

• Many studies were conducted several decades ago.
• Historical viral assays were less sensitive than modern tests.
• Several comparator medicines are now outdated.
• Numerous trials had small sample sizes.
• Some studies were open label or single blinded.
• Several analyses used historical rather than concurrent controls.
• Many studies were performed within one country or healthcare system.
• Geographic results may not generalise to UK populations.
• Concomitant treatment makes the peptide’s contribution difficult to isolate.
• Immune biomarkers were frequently used instead of clinical outcomes.
• Improved lymphocyte measures do not prove improved survival.
• Antibody titres do not prove fewer vaccine-preventable infections.
• Early positive sepsis evidence was not confirmed in the large TESTS trial.
• COVID-19 studies used changing and now-outdated standards of care.
• COVID-19 severity definitions differed between studies.
• Cancer studies frequently predated modern targeted therapies.
• Cancer studies often combined several active treatments.
• No established evidence supports healthy-person immune optimisation.
• No evidence establishes prevention of ordinary seasonal infections.
• No validated replacement threshold exists for low endogenous Ta1.
• No established long-COVID indication exists.
• No established ME/CFS indication exists.
• No human longevity benefit has been demonstrated.
• Research-market products may not match pharmaceutical thymalfasin.
• Free-base and acetate materials can be confused.
• N-terminal acetylation may not be confirmed.
• A high HPLC result may conceal important peptide impurities.
• Aggregation can increase immunogenicity concerns.
• Long-term use outside defined medical populations is poorly studied.

Reported Reactions

Clinical reports most commonly describe local reactions, discomfort, redness, fatigue, headache or flu-like symptoms.

Adverse-event reporting varies substantially between trials, and older studies may not meet current pharmacovigilance standards.

Immunogenicity

The native sequence may appear less likely to provoke antibodies than a highly modified foreign peptide.

Manufacturing impurities, aggregates, oxidation products and incorrect formulations can nevertheless create immune responses.

FDA specifically identified potential immunogenicity concerns for compounded injectable products.

Long-Term Safety

Long-term safety has not been established for healthy-person wellness, recurrent seasonal use or indefinite anti-ageing protocols.

Clinical exposure in one disease cannot determine safety in people with different autoimmune, cancer, transplant or inflammatory conditions.

Pregnancy and Breastfeeding

Adequate pregnancy and breastfeeding evidence is limited.

Immune signalling during pregnancy is highly regulated, and absence of obvious toxicity in general trials does not establish reproductive safety.

Paediatric Use

Paediatric suitability is indication and product specific.

A research vial should not be assumed appropriate because the endogenous peptide occurs naturally in the body.

Product-Quality Risks

• Incorrect amino-acid sequence
• Missing N-terminal acetyl group
• Deletion-sequence impurities
• Incomplete peptide coupling
• Incorrect C-terminal structure
• Deamidation products
• Oxidation products
• Incorrect acetate content
• Incorrect net peptide quantity
• Peptide aggregates
• Residual synthesis reagents
• Residual organic solvents
• Elemental impurities
• Unverified bacterial-endotoxin control
• Unverified sterile quality
• Incorrect storage or transport
• Certificates unrelated to the finished batch

Autoimmune Disease

Autoimmune conditions involve immune responses directed against the body’s own tissues.

A peptide described commercially as balancing immunity cannot be assumed to improve every autoimmune disorder.

Effects on antigen presentation, T cells and cytokines could differ between diseases and stages.

Cancer

Immune modulation might theoretically assist antitumour responses in one setting while worsening immune toxicity or interacting with treatment in another.

It should not be combined independently with chemotherapy or checkpoint inhibitors on the basis of online mechanistic claims.

Transplantation

Transplant outcomes depend on a controlled balance between infection prevention, immune recovery, graft acceptance and graft-versus-host effects.

Unsupervised immune stimulation could interfere with this balance.

Acute Infection

Severe infection can involve simultaneous inflammation and immune suppression.

Timing may determine whether a given immune effect is helpful, neutral or harmful.

What Meaningful Thymosin Alpha-1 Documentation Should Include

• Complete Thymosin Alpha-1 or thymalfasin identity
• Full 28-residue sequence
• Confirmation of N-terminal acetylation
• Confirmation of C-terminal Asn28
• Observed intact molecular mass
• Tandem-MS sequence evidence
• Net peptide-content assay
• Free-base or acetate-form declaration
• Quantitative counterion result
• Chromatographic purity
• Named and unknown impurity results
• Deletion-sequence profile
• Deamidation and oxidation results
• Aggregate assessment
• Water-content result
• Residual-solvent results
• Residual synthesis-reagent results
• Elemental-impurity assessment where appropriate
• Bacterial-endotoxin result where relevant
• Sterility result for a finished injectable medicine
• Finished-product batch number
• Testing-laboratory identity
• Analytical methods and acceptance criteria
• Stability and storage evidence
• A clear statement identifying tests not performed

Why “99% HPLC” Is Not Enough

HPLC area purity does not prove that the main peak has the correct sequence or N-terminal acetylation.

It does not establish net peptide amount, acetate content, aggregates, endotoxin control or sterile quality.

Different impurities may absorb ultraviolet light differently, making peak-area percentages an imperfect measure of actual mass composition.

A certificate for raw powder does not automatically describe the quality of the finished vial.

Physical and Chemical Characterisation

FDA described Thymosin Alpha-1 as an N-terminally acetylated 28-amino-acid peptide with a molecular weight of approximately 3,108.3 g/mol.

It identified insufficient information on individual impurities, total impurities, aggregates, bioburden and bacterial endotoxins in nominated or publicly available documentation.

Immunogenicity

FDA stated that peptide aggregation and synthesis-related impurities could create immunogenicity concerns for compounded injectable products.

Effectiveness

The agency reviewed hepatitis B, hepatitis C, HIV, COVID-19, vaccine response, melanoma, hepatocellular carcinoma, lung cancer, sepsis, transplant infections, COPD and ME/CFS.

It concluded that evidence did not support the proposed compounded uses and noted major limitations involving small studies, outdated comparators, biomarkers and design deficiencies.

Advisory-Committee Vote

On 4 December 2024, committee members voted separately on the free-base and acetate forms.

For each form, four members voted in favour of inclusion and seventeen voted against inclusion on the 503A Bulks List.

Members voting against inclusion cited a lack of compelling or convincing evidence of clinical effectiveness and safety for the reviewed uses.

How the MHRA Determines Whether a Product Is a Medicine

MHRA guidance states that a product may be medicinal when it is presented as preventing or treating disease.

A product may also be medicinal when it is intended to restore, correct or modify physiological functions through pharmacological, immunological or metabolic action.

Claims about preventing infection, restoring immunity, treating chronic viruses, improving vaccine response or supporting cancer treatment could contribute to medicinal-product classification.

The MHRA may assess the product name, website, label, testimonials, imagery, social-media content, instructions and intended customer use.

“Research Use Only” Wording

A research disclaimer does not automatically prevent a product from being classified as medicinal.

The complete commercial presentation matters, particularly where content encourages personal administration or promises health outcomes.

Advertising Restrictions

Regulation 279 of the Human Medicines Regulations restricts advertising a medicinal product unless the required marketing authorisation, registration or certificate is in force.

Prescription-only medicines are also subject to restrictions on public advertising.

This section provides general regulatory education and does not constitute legal advice.

Absence by name should not be treated as a permanent or product-independent guarantee.

Combination products can contain prohibited substances, and an undeclared ingredient may create an anti-doping violation.

Intravenous administration can also fall within prohibited-method rules independently of the active ingredient and medical indication.

Athletes are responsible for substances detected in their samples under strict-liability principles.

A current product-specific check through UK Anti-Doping, Global DRO or the relevant sports federation remains appropriate.

• Does the source identify the peptide as Thymosin Alpha-1 or thymalfasin?
• Is the complete 28-residue sequence stated?
• Is N-terminal acetylation confirmed?
• Is the C-terminal asparagine intact?
• Is the material free base or acetate associated?
• Is counterion acetate confused with acetylation?
• Was intact mass measured?
• Was tandem-MS sequence evidence provided?
• Were deletion sequences assessed?
• Were oxidation and deamidation measured?
• Were aggregates assessed?
• Was net peptide quantity measured?
• Was bacterial endotoxin tested?
• Was sterile quality demonstrated where relevant?
• Does the certificate match the finished batch?
• Was the clinical study randomised?
• Was it double blinded?
• Did it use a concurrent placebo group?
• Was the outcome a biomarker or a clinical event?
• Did the trial measure mortality, infection or quality of life?
• Was the study large enough for its primary endpoint?
• Did the prespecified endpoint succeed?
• Is an early positive trial quoted without the negative TESTS trial?
• Were current standard treatments used as comparators?
• Were viral assays compatible with modern standards?
• Can the peptide’s effect be separated from co-treatment?
• Was the finding independently replicated?
• Are healthy-person claims based on severely ill patients?
• Is overseas authorisation being presented as UK approval?
• Is the source selling the product it describes?

The reviewers and contributors are identified to provide clear authorship and accountability. Their inclusion does not represent endorsement of any research product, supplier, personal use, treatment claim or commercial statement discussed in this article.

Medical Director and Clinical Reviewer

Dr Laura Geige

Medical Director and Senior Aesthetics Practitioner at It’s Me & You Clinic, with a background in dentistry, medical aesthetics and cosmetic dermatology.

Read professional profile

Medical and Nutritional Sciences Reviewer

Dr Rimas Geiga

Medical doctor with a special interest in nutritional sciences, dietology, metabolic health and evidence based preventative care.

Read professional profile

Medical and Healthcare Reviewer

Dr Snieguole Geige

Dentist and medical doctor with experience across healthcare, preventative medicine and patient centred clinical standards.

Read professional profile

Dermatology Reviewer

Dr Giedre Narkiene

Medical doctor and board certified dermatologist with expertise in medical and cosmetic dermatology, skin health and patient safety.

Read professional profile

Medical and Gerontology Reviewer

Dr Veronika Matutyte

Medical doctor with training and professional experience in gerontology and healthcare management across clinical and hospital settings.

Read professional profile

Cosmetology and Skin Health Contributor

Livija Samušienė

Qualified cosmetologist with a Bachelor of Health Sciences in cosmetology and a professional interest in skin health, acne and evidence based aesthetic care.

Read professional profile